In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 156 for your search:

Drug:  fludeoxyglucose F 18
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice

Phase: Phase IV
Type: Diagnostic
Status: Active
Age: 60 to 80
Sponsor: Other
Protocol IDs: PROLOG, NCT00675168

CUP Project PET/CT

Phase: Phase IV
Type: Diagnostic
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: K36, NCT01469026

Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients With Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209

18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology

Phase: Phase III
Type: Diagnostic
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: R05-0076, NCT00207298

Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 15 to 70
Sponsor: Other
Protocol IDs: CDR0000531125, EORTC-20051, GELA-H10, IIL-EORTC-20051, EUDRACT-2005-002765-37, EU-20657, NCT00433433

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459

Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRUK-2007-006064-30, 2007-006064-30, CRUK-07/146, NCT00678327

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153

Phase III Randomized Study of Fludeoxyglucose F 18 Positron Emission Tomography Imaging in Patients Undergoing Chemotherapy Comprising Doxorubicin Hydrochloride, Bleomycin Sulfate, Vinblastine, and Dacarbazine For Stage IA or IIA Hodgkin Lymphoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 75
Sponsor: Other
Protocol IDs: CHNT-RAPID, RAPID, ISRCTN99811594, EU-20931, NCT00943423

10.

Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+

Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: LNH 2009-1B, NCT01285765

11.

OPTIMAL>60, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: DSHNHL 2009-1, NCT01478542

12.

Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)

Phase: Phase III
Type: Diagnostic, Treatment
Status: Approved-not yet active
Age: 18 to 60
Sponsor: Other
Protocol IDs: EORTC-20101-23101, 2011-005473-22, NCT01652261

13.

Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00600, U10CA080098, CDR0000521453, GOG-0233, ACRIN-6671, NCT00416455

14.

18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma

Phase: Phase II, Phase I
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 080200, 08-C-0200, NCI-08-C-0200, NCI-P07341, 8333, NCT00775268

15.

Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 6 to 120
Sponsor: Other
Protocol IDs: HITHD-01, NCT01005043

16.

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000669535, CRUK-CR0720-11, CRUK-MK-0752, EUDRACT-2008-004829-42, CR0720-11, NCT01098344

17.

Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer

Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I03017, NCT00199680

18.

Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cancer Cervix

Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: TMH/205/2004/Cx_PET STUDY, NCT00193752

19.

Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-Up of Nasopharyngeal Carcinoma.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 04-0264-C, NCT00188253

20.

Use of Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Tumor Response to Neoadjuvant Treatment for Distal Rectal Cancer

Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 717/05, NCT00254683

21.

Naltrexone in Treating Women With Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006LS016, UMN-0604M85308, UMN-2006LS016, NCT00379197

22.

The Utility of FDG-PET for Radiation Treatment in NSCLC

Phase: Phase II
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 20328, E-20328, NCT00385164

23.

Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 070058, 07-C-0058, NCI-07-C-0058, NCI-P6840, 7358, NCT00436215

24.

Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)